A18.1 Tuberculosis of genitourinary system

Name of the Condition

• Tuberculosis of genitourinary system
• ICD Code: A18.1

Summary

Tuberculosis of the genitourinary system is a form of extrapulmonary tuberculosis where Mycobacterium tuberculosis infects organs of the urinary or reproductive systems. This condition typically arises from the spread of TB bacteria from a primary site, such as the lungs, and can affect structures like the kidneys, bladder, ureters, or reproductive organs. It may present with localized symptoms or systemic signs of TB.

Causes

Tuberculosis of the genitourinary system is caused by infection with Mycobacterium tuberculosis. The bacteria usually spread to the genitourinary tract through the bloodstream or lymphatic system from an existing TB infection elsewhere in the body, such as the lungs or lymph nodes.

Risk Factors

• Close contact with individuals who have active tuberculosis.
• Immunocompromised states, including HIV/AIDS.
• History of tuberculosis infection.
• Poor socioeconomic conditions, which increase exposure risk.
• Living in or traveling to regions with high TB prevalence.

Symptoms

• Dysuria (painful urination).
• Hematuria (blood in urine).
• Urinary frequency or urgency.
• Pelvic pain or discomfort.
• Systemic symptoms of TB, such as fever, night sweats, or weight loss.
• In reproductive organs, symptoms may include abnormal discharge, menstrual irregularities, or pelvic pain.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging, and microbiological testing. Urine cultures for Mycobacterium tuberculosis are commonly used, along with imaging studies like ultrasound or CT to assess organ involvement. Biopsies or tissue samples may be examined for histological or molecular evidence of TB. Additional tests, such as tuberculin skin tests or interferon-gamma release assays, may support diagnosis.

Treatment Options

Standard anti-tuberculosis therapy (ATT) is the primary treatment, typically involving a combination of drugs like isoniazid, rifampicin, ethambutol, and pyrazinamide. Treatment duration is usually 6–9 months, depending on severity and response. Close monitoring for drug resistance and side effects is essential. Surgical intervention may be required in cases of severe organ damage or complications.

Prognosis and Follow-Up

With appropriate treatment, the prognosis for genitourinary tuberculosis is generally good, though recovery may take months. Follow-up care includes regular monitoring for treatment response, potential recurrence, or drug-related adverse effects. Long-term follow-up may be necessary to assess organ function and detect late complications.

Complications

• Kidney damage or renal failure.
• Urinary tract obstruction.
• Infertility or reproductive organ dysfunction.
• Spread of infection to other body parts.
• Drug resistance, which can complicate treatment.

Lifestyle & Prevention

• Avoid close contact with individuals who have active TB.
• Maintain good hygiene and ventilation in living spaces.
• Seek prompt treatment for latent or active TB to prevent spread.
• For those at high risk, consider preventive therapy as recommended by healthcare providers.

When to Seek Professional Help

Seek medical attention if you experience persistent urinary symptoms (e.g., pain, blood in urine), pelvic pain, abnormal discharge, or systemic signs of infection (e.g., fever, weight loss). Early diagnosis and treatment are critical to prevent complications.

Tips for Medical Coders

When coding A18.1, ensure documentation specifies the genitourinary site(s) affected (e.g., kidney, bladder, reproductive organs) to support the diagnosis. Verify that the condition is confirmed by microbiological, histological, or imaging evidence. If multiple genitourinary sites are involved, code A18.1 as the primary code, as it encompasses the entire system. Document any relevant clinical details to support the specificity of the diagnosis.